Home › Research › Disease mechanisms
Florzolotau (18F) retention is linked to neuropsychological performance in tauopathy
Atsushi Shimizu, Yu Iwabuchi, Shogyoku Bun, Memi Watanabe, Masahito Kubota, Sho Shimohama, Toshiki Tezuka, Keisuke Takahata et al.. Alzheimer s & Dementia, 2026-04-01
Topic: Brain proteins, microglia and lab models
In the AD continuum group, all cognitive test performances significantly correlated with tracer uptake, particularly in the left cortical areas. In the non-AD tauopathy group, strong correlations were observed with MMSE and TMT Part B performance. Neuropsychological performance and regional tau pathology distribution are correlated in patients with tauopathy, with differences between AD continuum and non-AD tauopathy. CLINICAL TRIAL REGISTRATION: This trial is registered with UMIN Clinical Trials (UMIN-CTR number: 000032027); submitted for registration on March 30, 2018; first patient enrolment was on July 3, 2018.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shimizu, A., Iwabuchi, Y., Bun, S., Watanabe, M., Kubota, M., Shimohama, S., et al. (2026). Florzolotau (18F) retention is linked to neuropsychological performance in tauopathy. Alzheimer s & Dementia. https://doi.org/10.1002/alz.71319
Vancouver
Shimizu A, Iwabuchi Y, Bun S, Watanabe M, Kubota M, Shimohama S, et al. Florzolotau (18F) retention is linked to neuropsychological performance in tauopathy. Alzheimer s & Dementia. 2026. doi:10.1002/alz.71319. PMID: 41923154.
BibTeX
@article{shimizu2026-41923154,
author = {Shimizu, Atsushi and Iwabuchi, Yu and Bun, Shogyoku and Watanabe, Memi and Kubota, Masahito and Shimohama, Sho and Tezuka, Toshiki and Takahata, Keisuke and others},
title = {{Florzolotau (18F) retention is linked to neuropsychological performance in tauopathy}},
journal = {Alzheimer s \& Dementia},
year = {2026},
doi = {10.1002/alz.71319},
pmid = {41923154},
url = {https://doi.org/10.1002/alz.71319}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In the AD continuum group, all cognitive test performances significantly correlated with tracer uptake, particularly in the left cortical areas.
- In the non-AD tauopathy group, strong correlations were observed with MMSE and TMT Part B performance.
- Neuropsychological performance and regional tau pathology distribution are correlated in patients with tauopathy, with differences between AD continuum and non-AD tauopathy.
- CLINICAL TRIAL REGISTRATION: This trial is registered with UMIN Clinical Trials (UMIN-CTR number: 000032027); submitted for registration on March 30, 2018; first patient enrolment was on July 3, 2018.
Why it matters
This imaging study found that neuropsychological test performance correlated with florzolotau (18F) tracer uptake in patients with tauopathy, with differences between the Alzheimer's disease continuum and non-Alzheimer's tauopathies. It concerns a marker of tau pathology, not a treatment, cure or prevention.
Study details
- Participants120
- Evidence strengthLow
How this study scored 37/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 120 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Daisuke Ito: h-index 9 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Keio University: institution h-index 735 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41923154) |
| Free to read | 2 / 2 | Free to read |
| Total | 37 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Disease mechanisms
Also tagged “phosphorylated”
733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.